Two of the five new nicotinic acid derivatives proved to have the antihypoxic properties in tests with mice exposed to acute normobaric hypoxic hypoxia with hypercapnia. Specifically, LKhT 4–19 (100 mg/kg) extended lifetime of the animals by 11 %; LKhT 6-19 doses of 50 and 100 mg/kg extended lifetime by 23 and 34 %, respectively. The antihypoxic effect of LKhT 6–19 (50 mg/kg) outperformed in 1.2 times mexidol (substance of comparison) at the similar dose and was highly competitive at the dose of 100 mg/kg. For reference, mexidol is a 3-hydroxypyridine derivative (ethylmethylhydroxypyridine succinate incorporating, similar to the substances in question, the pyrydine heterocycle). Besides, LKhT 6–19 (100 mg/kg) outperformed mexidol at the similar dose in 1.1 times.
In experiments with mice under various models of acute hypoxia a new synthesized compound LKhT 3-21 (50 mg/kg) showed a distinct antihypoxic activity. In comparison to mexicor (50 mg/kg), this compound increased lifespan in a hermetic chamber, under hemic hypoxia and histotoxic hypoxia by 107 %, 47 %, and 70 %, respectively. LKhT 3-21 exceeded mexicor in the effect against acute normobaric hypoxia with hypercapnia (in 1.9 times), acute hemic hypoxia (in 1.4 times) and acute histotoxic hypoxia (in 1.6 times).
Experiments with rats showed that two new nicotinic acid derivatives LKhT 6-20 and LKhT 7-20 at a dose of 50 mg/kg produce a vestibuloprotective effect involving an increased food intake after rotation in 1.3 and 1.9 times respectively, when compared to the control group. Effectiveness of LKhT 7-20 exceeded reference drug mexicor (ethylmethylhydroxypyridine succinate, equal dose) in 1.4 times, and previously tested LKhT 6-20 in 1.5 times.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.